Amgen (AMGN) Laps the Stock Market: Here's Why

Impact · against what's priced in

The article provides no new catalysts for Amgen, merely reiterating consensus earnings and revenue estimates that the market has already absorbed into the current share price.

AMGN+0.00

Already priced in

The price assumes

raised full-year revenue guidance of $38.2-$39.4 billion and non-GAAP EPS of $22.30-$23.50

The projected full-year earnings of $22.94 per share and revenue of $38.83 billion fall squarely within the guidance the market already assumes.

What AMGN's price assumes · Sep 12

• earnings
• healthcare
• revenue growth
• biotech
• fundamental analysis
• AMGN
• medical sector

Search tags